THE HEALTHCARE DECISION COMPANY
DEAD

Serial Number

87028341

Owner

Proove Biosciences, Inc.

Attorney

Patrick R. Delaney

Filing Date

May 6, 2016

Add to watchlist:

No watchlists yet
View on USPTO

THE HEALTHCARE DECISION COMPANY Trademark

Serial Number: 87028341

THE HEALTHCARE DECISION COMPANY is a trademark filed by Proove Biosciences, Inc. on May 6, 2016. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Proove Biosciences, Inc. (9 trademarks)

7706 Water Street
Fulton, MD 20759

Entity Type: 03

MYCROFT BIOANALYTICS, INC. (5 trademarks)

299 SOUTH MAIN STREET, SUITE 2300
SALT LAKE CITY, UT 84111

Entity Type: 03

Trademark Details

Filing Date

May 6, 2016

Registration Date

Not Registered

Goods & Services

Services in the nature of providing business information featuring billing information processing relating to genetic data

Conducting proprietary genetic testing for medical purposes to enable healthcare providers to provide patients with personalized medical treatment, to improve both the safety and efficacy of a patient's medical treatment, and to reduce costs; Providing genetic testing results and genetic-based medical analysis to healthcare providers to enable healthcare providers for medical purposes to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects, Providing medical and prescription related guidance to healthcare providers based on the genetic testing results, genetic-based medical analysis, and known drug-drug interactions; Conducting proprietary genetic testing for medical purposes using a simple cheek swab and genomic DNA isolation processes; Providing health-related information, consultancy or advisory services for health treatment purposes; Genetic counseling; Genetic tests for health treatment purposes; Providing information, advice or data on genetic testing results for medical purposes; Health treatment services, namely, providing medical prognosis information based on collected and processed genetic data; Medical services in the nature of providing genetic testing and genetic testing results for medical purposes

Conducting genetic research for scientific research purposes in connection with providing healthcare providers with personalized patient genetic-based medical analysis to enable healthcare provides to prescribe medications to their patients with genetic-based predictions as to how a patient will respond to prescribed medications; Conducting genetic research for scientific research purposes to enable healthcare providers to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects; Conducting genetic research in connection with providing healthcare providers prescription related guidance; Clinical research services for others, namely, collaborating with physicians, research organizations, patient advocacy groups, charitable organizations, and regulators to address issues related to personalized medicine; Consulting services in the fields of laboratory genetic testing or pharmacogenetics for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Genetic testing for scientific and medical research purposes to medical doctors, genetic scientists and healthcare professionals; Providing information in the field of pharmacogenetics or genetic research resources to medical doctors, genetic scientists and healthcare professionals; Providing genetic testing services for scientific research purposes and information in the field of pharmacogenetics and genetic research for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Research in the field of genetics or pharmacogenetics; Services in the nature of providing genetic testing results for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Providing temporary use of online non-downloadable computer software for controlling or managing patient record information, for the collection, editing, organizing, modifying, transmission, storage or sharing of data and information, and for scientific analysis of genetic sequences or alleles; Providing of genetic-based research information related to personalized medicine to healthcare providers, physicians, research organizations, patient advocacy groups, charitable organizations, and regulators

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 17, 2018 ASGN
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 2, 2017 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 2, 2017 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 2, 2017 GNFN
FINAL REFUSAL E-MAILED
Mar 2, 2017 GNFR
FINAL REFUSAL WRITTEN
Mar 2, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 22, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 22, 2017 TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 22, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 22, 2016 GNRN
NON-FINAL ACTION E-MAILED
Aug 22, 2016 GNRT
NON-FINAL ACTION WRITTEN
Aug 22, 2016 CNRT
ASSIGNED TO EXAMINER
Aug 22, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 11, 2016 NWOS
NEW APPLICATION ENTERED
May 10, 2016 NWAP